Stockscreener 앱 받기
13.29
2.23%
0.29
시간 외 거래:
13.53
0.24
+1.81%
전일 마감가:
$13.00
열려 있는:
$12.935
하루 거래량:
4.53M
Relative Volume:
3.45
시가총액:
$495.88M
수익:
$15.84M
순이익/손실:
$-308.48M
주가수익비율:
-2.0509
EPS:
-6.48
순현금흐름:
$-153.08M
1주 성능:
+44.93%
1개월 성능:
-2.99%
6개월 성능:
+101.36%
1년 성능:
+184.58%
1일 변동 폭
$12.80
$14.98
1주일 범위
$8.95
$14.98
52주 변동 폭
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
명칭
Uniqure N V
전화
1-339-970-7000
주소
PAASHEUVELWEG 25A, AMSTERDAM
QURE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
13.29 | 495.88M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-01 | 재개 | Chardan Capital Markets | Buy |
| 2024-12-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-02-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-17 | 업그레이드 | UBS | Neutral → Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-11 | 개시 | Berenberg | Buy |
| 2020-11-09 | 개시 | Jefferies | Buy |
| 2020-11-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-08-25 | 개시 | Raymond James | Strong Buy |
| 2020-07-31 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-06-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 개시 | Cowen | Outperform |
| 2019-12-03 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Outperform |
| 2019-10-11 | 개시 | Stifel | Buy |
| 2019-09-25 | 개시 | Bernstein | Outperform |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-07-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-07-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
모두보기
Uniqure N V 주식(QURE)의 최신 뉴스
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Yahoo Finance
uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold - Seeking Alpha
uniQure: Bullish On Near Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha
uniQure jumps on FDA breakthrough tag for Huntington’s disease drug - MSN
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic By Stocktwits - Investing.com India
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic - MSN
FDA grants breakthrough status to uniQure’s Huntington’s therapy By Investing.com - Investing.com South Africa
UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington's Disease Treatment - RagingBull
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? - Benzinga
uniQure (QURE) Surges After FDA Grants Breakthrough Status to Gene Therapy - GuruFocus
uniQure stock jumps on FDA breakthrough tag (QURE:NASDAQ) - Seeking Alpha
uniQure (QURE) Revenue and EPS Fall Short of Expectations - GuruFocus
uniQure shares soar on FDA breakthrough therapy designation By Investing.com - Investing.com South Africa
uniQure shares soar on FDA breakthrough therapy designation - Investing.com
FDA grants breakthrough status to uniQure’s Huntington’s therapy - Investing.com
uniQure (QURE) Secures Breakthrough Therapy Status for AMT-130 | QURE Stock News - GuruFocus
UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation - marketscreener.com
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease | QURE Stock News - GuruFocus
Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease - TradingView
uniQure N.V. Receives FDA Breakthrough Therapy Designation for AMT-130 in Huntington's Disease Treatment - Nasdaq
uniQure Announces FDA Breakthrough Therapy Designation - GlobeNewswire
Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results - Stock Titan
uniQure (NASDAQ:QURE) Shares Sold by Vanguard Group Inc. - Defense World
Hemophilia B Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme Sanofi - Barchart.com
uniQure CEO secures amended employment agreement By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Buys 58,246 Shares of uniQure (NASDAQ:QURE) - Defense World
uniQure CEO secures amended employment agreement - Investing.com
uniQure Amends CEO Employment Agreement - TipRanks
Alliancebernstein L.P. Has $3.60 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
NEVADA KING ANNOUNCES INCREASE OF PHASE III PROGRAM TO 30,000M, REFINES REGIONAL TARGETS AT ATLANTA - The Globe and Mail
Institutional owners may ignore uniQure N.V.'s (NASDAQ:QURE) recent US$190m market cap decline as longer-term profits stay in the green - simplywall.st
(QURE) Long Term Investment Analysis - news.stocktradersdaily.com
uniQure (NASDAQ:QURE) Now Covered by Analysts at Chardan Capital - The AM Reporter
Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval - insights.citeline.com
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
Stock Watch: Are Gene Therapy Prices Too High For Success? - insights.citeline.com
(QURE) Trading Report - Stock Traders Daily
uniQure (NASDAQ:QURE) Stock Rating Upgraded by StockNews.com - Defense World
Oppenheimer & Co. Inc. Buys New Stake in uniQure (NASDAQ:QURE) - Defense World
FY2025 Earnings Estimate for uniQure Issued By HC Wainwright - Defense World
uniQure (NASDAQ:QURE) Earns Buy Rating from HC Wainwright - Defense World
uniQure CFO Christian Klemt sells $107,407 in shares By Investing.com - Investing.com Australia
uniQure Reports 2024 Financial Results and Progress - TipRanks
uniQure’s chief medical officer sells shares worth $13,891 - Investing.com India
uniQure CFO Christian Klemt sells $107,407 in shares - Investing.com India
uniQure’s chief medical officer sells shares worth $13,891 By Investing.com - Investing.com South Africa
uniQure CEO Matthew Kapusta sells shares worth $291,628 By Investing.com - Investing.com South Africa
uniQure chief legal officer sells shares for $72,812 By Investing.com - Investing.com South Africa
Uniqure N V (QURE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):